Fig. 2.

The treatment efficacy of NBTXR3 + XRT + PLT (Combo) heavily depends on immune cells. Mice (n = 5) were treated by the combination therapy of NBTXR3 + XRT + PLT, as described in Fig. 1. In addition, αCD4 (500 µg), αCD8 (500 µg), and αAsialo GM1 (30 µL) antibodies were given via intraperitoneal injection on days 5, 7, 9, and 12, and 17 to deplete CD4⁺ T cells, CD8⁺ T cells, and NK cells, respectively. Mice were euthanized when the primary or the secondary tumors reached 14 mm in any dimension. A Tumor volume of the primary tumor. B Tumor volume of the secondary tumor. C Survival rates of the mice. Tumor volumes were compared by two-way analysis of variance and were expressed as mean tumor volume ± standard error of the mean ± SEM. Mouse survival rates were analyzed with the Kaplan–Meier method. P < 0.05 was considered statistically significant. *P < 0.05, **P < 0.01, ***P < 0.001, ****P < 0.0001, NS, not significant